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The AMP-activated protein kinase (AMPK), a
sensor of cellular energy status found in all eu-
karyotes, responds to changes in intracellular
adenosine nucleotide levels resulting frommet-
abolic stresses. Here we describe crystal struc-
tures of a heterotrimeric regulatory core frag-
ment from Schizosaccharomyces pombe AMPK
in complex with ADP, ADP/AMP, ADP/ATP,
and 5-aminoimidazole-4-carboxamide 1-b-D-
ribofuranotide (AICAR phosphate, or ZMP), a
well-characterized AMPK activator. Prior crys-
tallographic studies had revealed a single site
in the g subunit that binds either ATP or AMP
within Bateman domain B. Here we show that
ZMP binds at this site, mimicking the binding
of AMP. An analogous site in Bateman domain
A selectively accommodates ADP, which binds
in a distinct manner that also involves direct
ligation to elements from the b subunit. These
observations suggest a possible role for ADP
in regulating AMPK response to changes in
cellular energy status.
INTRODUCTION
The AMP-activated protein kinase (AMPK) is a multisub-
strate enzyme, conserved in all eukaryotic species, that
is activated in response to a variety of metabolic stresses
that impact cellular energy levels. AMPK activity helps
adapt cellular metabolism to match available energy re-
sources through regulation of key enzymes in each major
branch of cellular metabolism: fatty acid and sterol syn-
thesis and oxidation, sugarmetabolism, protein synthesis,
and DNA replication (Hardie, 2003; Kahn et al., 2005;
Kemp et al., 2003). AMPK activation depends both on
phosphorylation by upstream kinases (Hawley et al.,
2003) and cellular adenylate concentrations (Hardie,
2003). When intracellular ATP levels are low, active
AMPK inhibits numerous ATP-consuming pathways while
activating mobilization of intracellular energy stores to
produce ATP. Conversely, when ATP levels are high,Structure 15, 1285–12AMPK activity is inhibited, leading to enhancement of en-
ergy storage pathways and increased energy usage for
biosynthetic pathways. This regulatory mechanism helps
to adapt cellular metabolism to match cellular energy
resources (Hardie et al., 2006).
The biochemical activities of AMPKs have been best
characterized for the human enzymes. Activation of hu-
man AMPK depends on both a marked decrease in cellu-
lar ATP levels and phosphorylation by upstream kinases at
Thr172 (T189 in Schizosaccharomyces pombe protein) in
the activation loop of the a kinase domain (Hawley et al.,
1995). The binding of AMP allosterically activates the
phosphorylated enzyme (Yeh et al., 1980). AMP binding
also makes AMPK a poorer substrate for phosphatases
that dephosphorylate the activation loop threonine (Da-
vies et al., 1995; Sanders et al., 2007). High ATP levels in-
hibit the allosteric effects of AMP (Carling et al., 1987). The
budding yeast AMPK homolog (Saccharomyces cerevi-
siae Snf1p/Snf4p/Gal83p) has been extensively charac-
terized genetically and biochemically (Carlson, 1999; Har-
die et al., 1998). Unlike the mammalian enzyme, budding
yeast Snf1p/Snf4p/Gal83p does not appear to be acti-
vated by AMP in vitro (Wilson et al., 1996; Woods et al.,
1994). Nevertheless, budding yeast AMPK does become
activated under conditions which lead to energetic stress,
such as growth in low glucose (Wilson et al., 1996). Many
of the adaptive responses to glucose limitation which oc-
cur in humans are conserved in budding yeast, including
phosphorylation of acetyl CoA carboxylase, catabolite de-
repression, and induction of gluconeogenic genes (Carl-
son, 1999; Hardie et al., 1998). Although fission yeast (S.
pombe) AMPK subunits have high sequence homology
with AMPKs of other species, S. pombe AMPK has not
yet been characterized biochemically.
AMPKs are heterotrimeric enzymes comprised of a, b,
and g subunits. In humans, either two or three genes en-
code isoforms of each subunit, giving rise to 12 possible
heterotrimeric combinations (Kahn et al., 2005). The a
subunit includes a serine/threonine kinase domain in the
N-terminal region, and a C-terminal domain characteristic
of AMPKs that is required to form a complex with the b
and g subunits. AMPK b subunits contain two conserved
regions, the central glycogen-binding domain (GBD)
(Polekhina et al., 2005) and a C-terminal domain that
mediates complex formation with the a and g subunits.95, October 2007 ª2007 Elsevier Ltd All rights reserved 1285
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Structures of AMPK Complexed with ADP and ZMPFigure 1. Only ADP Binds in Bateman Domain A of the AMPK g Subunit
A cartoon representation of the AMPK regulatory timer core is shown with bound (A) ADP; (B) AMP; (C) AMP/ADP; and (D) ATP/ADP. In (A), two
orthogonal views are shown. Omit map difference density contoured at 3s is shown in magenta. The a subunit is colored in yellow, and b is in
blue. Bateman domains A and B of the g subunit are colored in light green and dark green, respectively.g subunits are composed of variable N-terminal regions
followed by four tandem repeats of cystathionine b-
synthase (CBS) domains (Bateman, 1997). Tandem pairs
of CBS domains, often termed Bateman domains, can
act as binding domains for small-molecule ligands (Scott
et al., 2004).
We recently reported the crystal structure of a heterotri-
meric core fragment from fission yeast AMPK (Townley
and Shapiro, 2007). This structure revealed a single ligand
binding site, in Bateman domain B of the g subunit which
could accommodate either AMP or ATP, which we now
refer to as ‘‘site B’’. AMP or ATP binds to site B, at the in-
terface between CBS3 and CBS4, with the nucleotide
phosphates positioned within a domain-spanning aque-
ous pore referred to as the ‘‘phosphate tunnel’’. The ob-
servation of this single binding site in Bateman domain B
was unexpected, because biochemical studies on iso-
lated human g2 subunits suggested that Bateman domain
A would also contain a nucleotide binding site (Scott et al.,
2004). This discrepancy could be due to either a different
regulation mechanism between the mammalian and yeast
enzymes, or to differences between the behavior of the g
subunit in isolation and in the context of the abg trimer.
Here we report structures of S. pombe AMPK core het-
erotrimer in complex with ADP, AMP/ADP, ATP/ADP, and1286 Structure 15, 1285–1295, October 2007 ª2007 Elsevier Ltthe well-characterized AMPK activator 5-aminoimidazole-
4-carboxamide 1-b-D-ribofuranotide (AICAR phosphate,
or ZMP). These structures show that both ADP and ZMP
bind within Bateman domain B (site B) in a manner similar
to that of AMP and ATP. However, structures of ADP-con-
taining complexes show that an additional ADP molecule
binds to a unique ADP-specific site in Bateman domain A,
which we now refer to as ‘‘site A’’. This ADP-specific site
also includes direct ligand interactions with residues of a
mobile loop from the b subunit which caps the phosphate
tunnel. These new structural observations suggest the
possibility for an allosteric regulatory role of ADP in AMPK
response to adenylate levels in S. pombe, and raise the
possibility that ADP/AMPK interactions may play a direct
regulatory role in the response to cellular energy status.
RESULTS
Structure of the AMPK Core in Complex with ADP
The overall structure of theS. pombeAMPK/ADP complex
is very similar to those of the AMP- and ATP-bound struc-
tures (root-mean-square deviation [rmsd] 0.9 A˚ of all
aligned Ca atoms), but is remarkably different in that two
molecules of ADP are bound (Figure 1; close-up density
images for each nucleotide complex structure are shownd All rights reserved
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Structures of AMPK Complexed with ADP and ZMPTable 1. Data Collection and Refinement Statistics
ADP AMP/ADP ATP/ADP ZMP
Data Collection
Space group C2 C2 C2 C2
a, b, c (A˚) 168.9, 78.4, 108.9 168.7, 78.2, 109.0 168.3, 78.4, 109.0 168.5, 78.1, 108.5
a, b, g () 90, 124.1, 90 90, 124.2, 90 90, 124.2, 90 90, 124.0, 90
Resolution (A˚) 2.8 (2.9–2.8) 2.7 (2.8–2.7) 2.4 (2.49–2.4) 3.0 (3.11–3.0)
Rsym 0.130 (0.259) 0.107 (0.472) 0.087 (0.517) 0.18 (0.63)
I/sI 12.0 (3.1) 7.4 (1.5) 19.7 (3.5) 4.6 (1.5)
Completeness (%) 93.3 (68.4) 96.8 (81.6) 99.2 (99.2) 89.3 (96.0)
Redundancy 5.8 3.4 7.0 3.9
Refinement
Resolution (A˚) 50–2.8 50–2.7 50–2.4 50–3.1
Number of reflections 26,690 31,521 42,837 19,774
Rwork/Rfree 0.191/0.276 0.208/0.290 0.182/0.253 0.235/0.297
B factors (A˚2)
All atoms 51.3 58.0 54.5 59.6
Protein 51.3 58.7 55.8 59.5
Ligand 51.9 57.0 48.0 86.2
Water 49.6 56.3 57.7 N/A
Rms deviations
Bond lengths (A˚) 0.010 0.014 0.016 0.011
Bond angles () 1.292 1.619 1.706 1.439
One crystal was used per data set. Values in parentheses are for the highest resolution shell.
N/A, not applicable.
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Rfree = Rwork was calculated using 5% of the reflection data chosen randomly and omitted from the start of refinement.in Figure S1 in the Supplemental Data available with this
article online; crystallographic statistics are shown in
Table 1). The previously reported AMP and ATP complex
structures (Townley and Shapiro, 2007) revealed a single
nucleotide binding site at the CBS3-CBS4 interface of
Bateman domain B (site B). In contrast, ADP binds at two
quasi-equivalent sites, one in each Bateman domain
(Figures 1A and 2B). Similar to the structures of AMP-
and ATP-bound AMPK, one molecule of ADP is bound at
site B by interactions similar to those of ATP and AMP.
Briefly, the adenine base is stabilized in a predominantly
hydrophobic binding pocket via stacking interactions
with hydrophobic residues from both CBS3 and CBS4,
namely gI216, gP220, and gI303 (Figure 3A). In addition,
a pair of hydrogen bonds, one between the 60-amino group
and the backbone carbonyl oxygen of gA196, the other
between 10-aza group and the main-chain nitrogen atomStructure 15, 1285–1of gA196, further stabilizes the adenine ring in its position.
The free hydroxyl groupsof the ribosemoiety are hydrogen
bonded to the side-chain carboxyl of gD308 as well as the
hydroxyl of T191. The a-phosphate makes salt-bridge
interactions with two arginine residues from CBS2, gR139
and gR141, while the b-phosphate interacts with side
chains from gR290 and gS217.
The second ADP molecule, bound in Bateman domain
A in a site we refer to as site A, also makes a network of
interactions with surrounding protein residues mainly
from the g subunit, but is also directly ligated by residues
from the b subunit (Figures 3B and 3C). The adenine ring
is stabilized by hydrophobic interactions with the gI35
and gI55 side chains as well as hydrogen bonds between
the 60-amino group and 10-aza group and the main-chain
nitrogen and carbonyl oxygen atoms of gI35. In addition,
there are water-mediated hydrogen-bond interactions295, October 2007 ª2007 Elsevier Ltd All rights reserved 1287
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Structures of AMPK Complexed with ADP and ZMPFigure 2. Site A Binds ADP Irrespective of the Nucleotide Bound at Site B
Structures of the AMPK regulatory trimer core in complex with (A) AMP/ADP; (B) ADP; and (C) ATP/ADP. The region corresponding to a putative pseu-
dosubstrate sequence (see text) is highlighted in pink. Bateman domain A is shown in light green and Bateman domain B is in dark green. Closest
approach distances between nucleotides bound at sites A and B are indicated.between the N7 of the adenine ring and the main-chain ni-
trogen atoms of gV56 and gS57. The a-phosphate makes
salt-bridge interactions with gR142 fromCBS2 and gR287
fromCBS4, and the b-phosphate interacts with side-chain
atoms from gT162, gR165 from CBS2, and gR287 and
gH289 from CBS4. The interaction of the b-phosphate
with four surrounding residues appears to be stronger
than that of the a-phosphate (Figure 3B). Thismay partially
explain the ADP-specific binding character of this site. We
note further that cocrystallization experiments including
AMP or ATP at concentrations up to 10 mM reveal no
ligand binding to site A (data not shown), illustrating a
high degree of specificity for ADP. The side-chain confor-
mation of the residues interacting with ADP in site A are
mostly similar to those seen in the unliganded structure
(2.8 A˚ resolution; data not shown) and AMP- and ATP-
bound structures (Townley and Shapiro, 2007), except
for gR287 and gH289, which undergo significant changes
in side-chain conformation (Figure 3B).
Importantly, ADP binding at site A also involves residues
from the b subunit. The free hydroxyl groups of the ribose
moiety hydrogen bond to side chains from residues
bD250, bQ251, and bS252, within a polar loop we have re-
ferred to as the ‘‘b flap’’ (Townley and Shapiro, 2007). The
b flap, encompassing residues b244–b255, appears highly
flexible in the several structures we have determined, and
structural rearrangements upon ligand binding could thus
be involved in allosteric regulation. The b flap adopts
a new conformation due to interactions with the bound
ADP (Figure 3B). Outside the vicinity of site A, only subtle
conformational differences are found between the ADP
and highly similar ATP and AMP complex structures.
Sites A and B, though clearly distinct, exhibit a high
degree of similarity in overall architecture (Figure 4). Each
is composed of a hydrophobic pocket that sandwiches1288 Structure 15, 1285–1295, October 2007 ª2007 Elsevier Ltthe adenine base, a set of positively charged side chains
that coordinate the phosphate moiety, and aspartic acid
side chains that hydrogen bond with the 20- and 30-hydro-
xyls of the ribosemoiety. However, substantial differences
are also evident. Perhaps most notably, in site A, the
ribose moiety is bound by residues from the b subunit,
rather than the g subunit as in site B. In site A, the base
makes direct contact with only a single hydrophobic
side chain, from gI55. In contrast, in site B, the base is
sandwiched between three hydrophobic side chains,
gI216, gP220, and gI303. When the adenine rings of
ADP bound in sites A and B are superposed, it can be
seen that the phosphate groups project in opposite direc-
tions toward positively charged side chains in their re-
spective binding pockets (Figure 4). Interactions with the
nucleotide phosphate groups, however, reveal the most
significant differences. The site A phosphate groups are
coordinated by three arginine and one histidine side chain.
Two arginine residues (gR165 and gR287) and one histi-
dine (gH289) coordinate the b-phosphate, and two argi-
nine side chains (gR142 and gR287) directly interact with
the a-phosphate. In site B, only a single arginine side chain
(gR290) coordinates the b-phosphate, while two (gR139
and gR141) bind the a-phosphate. Although these differ-
ences are highly suggestive of a structural basis for ADP
preference for site A in S. pombe AMPK—because the
terminal phosphate from ADP is highly coordinated—
sequence differences in other species make it difficult to
predict their nucleotide binding specificity at this site.
Structure of the AMPK Core in Complex with
AMP/ADP and ATP/ADP
The finding of an ADP-specific site in Bateman domain A
led us to ask whether the AMPK core trimer could
accommodate binding to different nucleotides ind All rights reserved
Structure
Structures of AMPK Complexed with ADP and ZMPFigure 3. ADP Binding
(A) Stereo diagram of ADP binding at site B within Bateman domain B of the g subunit.
(B) Stereo diagram of ADP binding at site A within Bateman domain A of the g subunit. The unliganded structure of the b and g subunits are shown in
transparency, illustrating the changes in conformation induced by ligand binding. For clarity of the figure, residue gI55, which contacts the adenine
base, is not shown.
(C) The final sA-weighted 2Fo  Fc map contoured at 1.5s around the ADP bound in site A.combination as would be found in living cells. Results from
cocrystallization experiments where equal concentrations
of ADP and either ATP or AMP were included show thatStructure 15, 1285–12site A can bind ADP irrespective of the nucleotide bound
at the Bateman domain B site. Further, ADP binding at
this site does not perturb the ability to bind ATP or AMP95, October 2007 ª2007 Elsevier Ltd All rights reserved 1289
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Structures of AMPK Complexed with ADP and ZMPFigure 4. Comparison of ADP Binding by Site A and Site B
In this figure, the adenine rings of the ADP molecules bound in site A and site B of two AMPK trimers were superposed in order to enable comparison
of ADP-binding residues. Site A and its bound ADP are shown in yellow, and site B and its ligand are in green. All protein atoms are from the g subunit,
except for the ribose-coordinating amino acids of site A, which are from the b subunit.in Bateman domain B (Figures 1 and 2). The residues that
ligate ADP, AMP, or ATP are identical in the one- and two-
nucleotide-bound structures, suggesting that the function
of site B is likely to be largely independent of site A. How-
ever, as site B is occupied in each of the complex struc-
tures reported here, it remains possible that binding at
site A may depend on ligand binding at site B.
Structure of the AMPK Core in Complex with the
AMPK Activator ZMP
AICAR phosphate is a potent activator of mammalian
AMPKs (Buhl et al., 2002; Fiedler et al., 2001; Pold et al.,
2005; Song et al., 2002). AICAR is taken up by cells and
phosphorylated to produce AICAR-phosphate, also called
ZMP, which binds to and activates AMPK. The overall
structure of the ZMP-bound AMPK regulatory trimer is
very similar to the AMP-bound structure, with an rmsd of
0.8 A˚ over all Ca atoms. Omit maps show excellent den-
sity for a ZMP molecule in site B of Bateman domain B
(Figure 5A). No density was present in the ADP-specific
site A. ZMP binding at site B (Figure 5B) closely mimics
the binding of AMP. The N2 and O5 atoms make tight
hydrogen bonds with the main-chain carbonyl oxygen and
nitrogen atoms of gA196, and the N3 atommakes a hydro-
gen bond with the hydroxyl group of gT191. The ribose
moiety makes interactions with gD308 and gT191 identi-
cal to those seen in the AXP-bound structures. The phos-
phate moiety is hydrogen bonded to side-chain atoms
from gS217, gS305, and gR141. That the close AMP
analog ZMP binds only at the AXP binding site in Bateman
domain B, but not at the ADP-specific site in Bateman do-
main A, further underscores the specificity of site A, and is
consistent with the AMP-mimetic effects on human AMPK
activity exhibited by ZMP.1290 Structure 15, 1285–1295, October 2007 ª2007 Elsevier LtdSpecificity for Adenosine Nucleotides
When AMPK was crystallized in the presence of 10 mM
GMP, there was no density indicating bound ligand in
either site (data not shown). Specificity for binding adeno-
sine but not guanosine nucleotides canbe easily explained
by the structures of the nucleotide binding sites. In both
site A and site B, the adenine ring is stabilized not only
via hydrophobic interactions with surrounding aliphatic
residues but also by tight hydrogen bonds with the main-
chain nitrogen and carbonyl atoms of gI35 (site A) and
gA196 (site B). These pairs of hydrogen bonds ensure
the specificity of AMPK for adenosine nucleotides over
structurally similar guanine nucleotides, as a carbonyl
group in place of the amino group at position 6 of the
base would be expected to disrupt this hydrogen-bond-
ing network. We also sought to answer the question of
whether AMPKcould accommodate the binding of a cyclic
nucleotide. We cocrystallized AMPK with cyclic AMP and
determined the structure from these crystals (data not
shown). Although only at 3.5 A˚ resolution, the resulting
electron density map clearly shows a bound cyclic AMP
molecule in site B of Bateman domain B, but no ligand
density is apparent in the ADP-specific site A of Bateman
domain A. The implication of cyclic AMP binding is
unknown, but given the very low intracellular concentration
of cyclic AMP as compared to that of AMP, cyclic AMP is
not likely to be a physiologically relevant regulatory ligand.
DISCUSSION
Implications of ADP Binding to a Unique Site in
Bateman Domain A
The finding that S. pombe AMPK specifically binds ADP
at a unique site raises new questions about regulatoryAll rights reserved
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Structures of AMPK Complexed with ADP and ZMPFigure 5. ZMP Binding
(A) Stereo diagram of ZMP bound in site B shown with an Fo  Fc map contoured at 2.5s.
(B) Stereo diagram of detailed interactions with ZMP; polar interactions are indicated by dashed lines.mechanisms of AMPKs. It has been postulated that
AMPKs respond to adenylate energy charge (E.C.), amea-
sure of the intracellular energy stored in adenylate-bound
phosphate bonds, usually expressed as a ratio of concen-
trations of the adenosine nucleotides:
E:C:=
ATP+ 1
2
ADP
ATP+ADP+AMP
:
It has been shown convincingly that human AMPKs re-
spond to levels of both ATP and AMP (Hardie et al., 2006),
but response to ADP has not been reported. The finding
that ADP binds AMPK at a unique site brings a new focus
to the potential role of ADP in AMPK regulation. Whether
ADP-specific binding is a feature unique to fission yeast,
or whether it is a property shared by AMPKs of other
species, is yet to be determined.Structure 15, 1285–12The biological implications of ADP binding at this unique
site are not yet clear. X-ray diffraction experiments re-
ported here show that neither AMP nor ATP binds at site
A, even at nucleotide concentrations as high as 10 mM.
Previous studies have shown that isolated human AMPK
g subunits can bind two molecules of AMP, presumably
one in each of the two Bateman domains, in a highly coop-
erative manner (Scott et al., 2004). It has also been sug-
gested that in the human g2 subunit, site A is inaccessible
until AMP has bound at site B (Scott et al., 2004). g2 mu-
tations in both Bateman domain A (g2R302Q, g2H383R,
g2T400N, corresponding to gV56, gR141, gT162 in the
S. pombe enzyme) and domain B (g2N488I, g2R531G,
g2R531Q, corresponding to gS247, gR290 in S. pombe
enzyme) cause heart disease in humans, and also interfere
with AMP activation of AMPK in vitro (Burwinkel et al.,95, October 2007 ª2007 Elsevier Ltd All rights reserved 1291
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Structures of AMPK Complexed with ADP and ZMPFigure 6. Sequence Conservation of Nucleotide Interactions in AMPK
(A) Sequence alignment of S. pombe AMPK g subunit, human AMPK g1, g2, and g3 subunits, and the S. cerevisiae homolog snf4. Residues that
interact with ADP in site A are denoted by purple triangles, and residues that interact with ADP in site B are denoted by green triangles. The pink
line denotes the pseudosubstrate sequence.
(B) Sequence alignment of the S. pombe AMPK b subunit, human AMPK b1 and b2 subunits, and S. cerevisiae sip2p. Residues that interact with the
ADP in site A are denoted by purple triangles.2005; Daniel and Carling, 2002; Scott et al., 2004). These
mutational data suggest that both sites A and B play a role
in AMPK regulation.
Recently, Scott and colleagues proposed that regu-
lation of human AMPK involves a pseudosubstrate regula-
tory sequence in the CBS2 subdomain of the g2 sub-
unit. In the human protein, this sequence resembles sites
phosphorylated by AMPK on target proteins, but lacks a
phosphorylatable amino acid (Scott et al., 2007). This se-
quence encompasses residues g370–391, corresponding
to g128–147 inS. pombe, a region of low sequence identity
(Figure 6A). In their study, this pseudosubstrate sequence
is proposed to act by binding to and obstructing the sub-
strate-binding groove on the a subunit kinase domain in
the absence of AMP. This model suggests that the initial
binding of AMPoccurs at site B,which thenpromotesbind-
ing of a second AMP molecule at site A. Subsequent
binding of AMP to domain Awould thenweaken or prevent
interaction of the pseudosubstrate sequence with the
a subunit kinase domain. Although this seems an attrac-1292 Structure 15, 1285–1295, October 2007 ª2007 Elsevier Ltive model for regulation of human AMPK, the low
sequence conservation of this region in yeast AMPKs
suggests that if this regulatory model is correct for human
AMPK, it is not likely to be shared by the S. pombe
enzyme. In our structures, gR141 and gR142 within this
putative pseudosubstrate sequence may play a role in
the crosstalk between two binding sites, with gR141 ligat-
ing the phosphate of the site B nucleotide, and gR142
ligating the nucleotide phosphate from site A. The cooper-
ative binding of two molecules of AMP reported for the
human g subunits may involve the analogous residues of
the human enzyme, and would require that the human
site A accommodate AMP.
Despite the attractiveness of the pseudosubstrate
model, analysisof theS.pombeAMPKstructures suggests
that much of the proposed pseudosubstrate region will be
rigidly bound in the g subunit, and it is not clear how AMP
binding could induce large structural rearrangements. This
region includes two secondary structure elements, a7
and b4. The b4 strand is packed beneath the CBS1-CBS2td All rights reserved
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Structures of AMPK Complexed with ADP and ZMPlinker, and would thus be unavailable for kinase domain
interaction. a7 is surface exposed, but makes significant
hydrophobic contacts with the core of the g subunit. Fur-
ther work will be needed to test and gain a full understand-
ing of the pseudosubstrate regulatory model. We recently
proposedanalternative regulatorymodelwhich suggested
that electrostatic differences between AMP and ATP
bound at site B might be important in modulating inter-
actions with the a subunit kinase domain (Townley and
Shapiro, 2007). However, the observation of a second nu-
cleotide binding site in Bateman domain A suggests that
the regulatory mechanism is likely to be more complex.
Bateman domains A and B of S. pombe AMPK share
50% sequence similarity with those of the human homo-
logs (Figure 6A). Therefore, structures of S. pombe AMPK
should provide a good overall model for the human AMPK
g subunits. However, it remains possible that nucleotide
interactions could differ in the human proteins. All of
the nucleotide-ligating residues of site B are conserved
between S. pombe and human enzymes. However, the
ADP-ligating residues reported here for site A are con-
served in human g subunits with the following exceptions.
First,gR287 is aglutamate inhumanAMPKg subunits (Fig-
ure 6A). This residue interacts with the b-phosphate of
ADP, and an acidic side chain would be expected to abol-
ish this interaction, potentiallymakingADPa less favorable
binding ligand. These sequence differences suggest the
possibility for differences between mammalian and yeast
AMPKs in site A nucleotide interactions. Second, two of
the residues from the b flap (Figure 6B) which interact
with the ribose moiety of ADP, bQ251 and bS252, are not
conserved in human AMPK b subunits. However, bD250
is conserved in human, and thus the ribose hydroxyl
groups could potentially still hydrogen bondwith an aspar-
tate side chain. In light of these differences, the nucleotide
binding configuration cannot bepredictedwith confidence
for the human protein. A definitive answer to this question
must await structures of a mammalian family member.
Conclusions
AMPK is among the most promising molecular targets for
treatment of metabolic disorders, particularly obesity and
its common complication, type II diabetes (Winder and
Hardie, 1999). Two existing major classes of insulin-sensi-
tizing drugs, the biguanides and the thiazolidinediones,
may exert some or all of their therapeutic effects by acti-
vating the AMPK system. However, both of these drug
classes appear to activate AMPK indirectly, either by
inhibiting the respiratory chain (in the case of thiazolidine-
diones) or by stimulating release of the hormone adipo-
nectin (Brunmair et al., 2004; El-Mir et al., 2000; Owen
et al., 2000). The use of the AMPK activator AICAR has
shown promising results for diabetes treatment in rodent
studies (Buhl et al., 2002; Fiedler et al., 2001; Pold et al.,
2005; Song et al., 2002). However, AICAR administration
is accompanied by toxic side effects, likely because the
active derivative of AICAR, ZMP, also modulates other
AMP-sensitive enzymes such as glycogen phosphorylase
(Longnus et al., 2003) and fructose-1,6-bisphosphataseStructure 15, 1285–(Vincent et al., 1991). This leaves open the question of
whether compounds can be found that directly activate
AMPK but have higher specificity. The AMP-binding do-
mains of AMPK g subunits therefore present promising
targets for the rational development of new drugs.
The structures of fission yeast AMPK in complex with
adenosine nucleotides and ZMP described here provide
amodel that will have both similarities with and differences
from the human homolog. All of the amino acids in site B
that coordinate AMP, ADP, and ATP are conserved in
the human enzyme, and most but not all of those involved
in nucleotide coordination at site A are also conserved
(Figure 6). Nonetheless, it remains possible that there
are mechanistic differences in the regulation of the human
and yeast enzymes that will not become clear until struc-
tures of the human protein are obtained. This possibility is
heightened by the observation that the S. cerevisiae
AMPK, the snf1 complex, does not appear to be activated
in response to AMP (Rudolph et al., 2007; Woods et al.,
1994). A prevailing view has held that AMPK regulation de-
pends primarily on AMP and ATP concentrations (Hardie
et al., 2006), and the role of ADP in AMPK regulation has
not been previously explored. Our finding that fission
yeast AMPK binds ADP at a unique site raises the possibil-
ity of a role for ADP in AMPK regulation and thus provides
a potential new direction for future investigations.
EXPERIMENTAL PROCEDURES
Expression, Purification, and Crystallization of the S. pombe
AMPK Regulatory Trimer
The regulatory domain of the AMPK heterotrimeric complex was
expressed and purified as previously reported (Townley and Shapiro,
2007). Crystals of AMPK in complex with ligands were grown from
hanging drops comprised of a 1:1 ratio of 6 mg/ml protein and 6%–
10% PEG3350, 0.1 M sodium citrate (pH 5.5), with various ligands.
For the ADP-bound crystal, 3 mM ADP was used in crystallization
setups; 5 mM AMP/5 mM ADP and 5 mM ATP/5 mM ADP were
included in the nucleotide mixture containing crystals. For the ZMP-
bound crystal, 2 mM ZMP was included in the crystallization drops.
Cocrystals were also produced with cAMP (5 mM) and GMP (10
mM), though GMP fails to bind to the protein. The crystals were cryo-
preserved in mother liquor supplemented with 30% ethylene glycol
before flash-freezing in liquid nitrogen.
Data Collection and Structure Refinement
Diffraction data were collected on single crystals frozen at 100K at
Northeastern Collaborative Access Team beamline ID24 at the Ad-
vanced Photon Source (Argonne, IL, USA), and processed with the
program HKL2000 (Otwinowski and Minor, 1997). Ligand-bound
structures were refined using the coordinates of the isomorphous
ATP-bound (Protein Data Bank [PDB] code: 2OOY) structure of S.
pombe AMPK (Townley and Shapiro, 2007). Manual rebuilding was
done with Coot (Emsley and Cowtan, 2004), and refinement was per-
formed using REFMAC (Murshudov et al., 1997) implemented in the
CCP4 program suite (CCP4, 1994). All molecular graphics figures
were generated with the program PyMOL (DeLano Scientific, LLC,
Palo Alto, CA, USA).
Supplemental Data
Supplemental Data include one figure and can be found with this
article online at http://www.structure.org/cgi/content/full/15/10/
1285/DC1/.1295, October 2007 ª2007 Elsevier Ltd All rights reserved 1293
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